SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

DIA is experiencing extreme volatility as market sentiment fluctuates rapidly with headlines regarding the 'Iran war,' driving sharp swings tied to perceived de-escalation versus renewed threats and escalating oil prices. The community is actively debating whether ongoing geopolitical instability and a significantly weak jobs report will lead to a broader market downturn or a powerful short squeeze as traders seek entry points.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble (RUM) is buzzing as its strategic alignment with Tether, including a substantial ownership stake and commitments for advertising and cloud services, alongside the Northern Data acquisition, fuels investor optimism for significant revenue growth and a potential short squeeze, contrasting with skepticism over its past share performance.

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

Aldeyra Therapeutics is trending due to its upcoming March 16 PDUFA date for dry eye treatment reproxalap, following a three-month FDA extension to review additional field trial data, which has intensely polarized community sentiment. Bulls highlight a previously received draft label and the drug's rapid efficacy, while bears emphasize two prior Complete Response Letters, a recent executive resignation, and concerns over the company's financial runway.

Draganfly, Inc. engages in the manufacture and sale of commercial unmanned aerial vehicle systems and software serving the public safety, agriculture, industrial inspections, security, mapping, and surveying markets. Its products include quad-copters, fixed wing aircrafts, ground based robots, hand held controllers, and software used for tracking, live streaming, and data collection. The firm also offers custom engineering, training, simulation consulting, as well as data and flight training services. The company was founded by Zenon Dragan and Christine Dragan in 1998 and is headquartered in Saskatoon, Canada.

Draganfly Inc

Draganfly (DPRO) is drawing significant attention from new defense contracts, including an international military order and providing drones to U.S. Air Force Special Operations, amplified by prospects from Canada's substantial defense industrial strategy. Community discussion balances enthusiasm for its role in a growing drone sector against concerns over a recent capital raise and not being selected for the DoD's initial Gauntlet I program.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is seeing a strong rebound, propelled by President Trump's comments suggesting the Iran war is "very complete" and oil prices sharply reversing. This has sparked a "V pump" celebration among bulls, while skeptics on the other side decry it as a market "manipulation" disconnected from the ongoing geopolitical situation and underlying economic risks.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. ($BNAI) is experiencing intense community interest following the recent closing of a significant AI licensing partnership in Africa, which bulls are pointing to as a catalyst for a massive short squeeze. With extremely high cost-to-borrow rates and a low float, the stock is drawing fervent speculation for substantial upside amidst a "no-sell" movement among eager retail traders.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending amid high anticipation for imminent top-line Phase 3 REGAL trial results for its GPS immunotherapy, with community bullishness fueled by interpretations of trial delays as a sign of extended patient survival and recent CEO commentary hinting at 'curative outcomes,' largely dismissing short-seller FUD.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as its Q4 earnings massively exceeded expectations, propelling an after-hours surge and reinforcing community optimism about Miplyffa's strong growth trajectory and imminent European regulatory approval.

What is Tron? Tron's mission is to build a truly decentralized internet and aims to be the largest blockchain-based operating system in the world, known as the TRON protocol. The TRON protocol will offer high scalability, high availability, and high throughput computing to serve decentralized applications via smart contracts. Ethereum EVM-based smart contracts will be compatible and deployable on the TRON network as such Solidity developers do not have to rewrite their applications.  Why Tron? Since TRON protocol does not rely on proof of work or mining, instead governed by nodes located around the world, it is decentralized while providing high throughput for transactions on the blockchain. This is suitable for dapps that require high speed transactions especially games. There are a number of tokens already issued on the TRON network and the decentralized exchanges TRX.market has launched.  On July 24th 2018, TRON acquired BitTorrent, one of the largest P2P file sharing protocol. As a result of the acquisition, BitTorrent Token (BTT) was launched as the cryptocurrency to power the economics on the BitTorrent network. The Token will be used to inceltivize file sharing and storage within the network.

Tron

TRX is trending amidst widespread community discussion about its deepening ties with Tether and Rumble for creator payments and cloud services, reinforcing its position as a key network for efficient stablecoin transfers globally. Investors also note its perceived market stability and recent integration with Coinbase's Base network, furthering its ecosystem reach.

Tether (USDT) is a cryptocurrency with a value meant to mirror the value of the U.S. dollar. The idea was to create a stable cryptocurrency that can be used like digital dollars. Coins that serve this purpose of being a stable dollar substitute are called “stable coins.” Tether is the most popular stable coin and even acts as a dollar replacement on many popular exchanges! According to their site, Tether converts cash into digital currency, to anchor or “tether” the value of the coin to the price of national currencies like the US dollar, the Euro, and the Yen. Like other cryptos it uses blockchain. Unlike other cryptos, it is [according to the official Tether site] “100% backed by USD” (USD is held in reserve). The primary use of Tether is that it offers some stability to the otherwise volatile crypto space and offers liquidity to exchanges who can’t deal in dollars and with banks (for example to the sometimes controversial but leading exchange Bitfinex)  The digital coins are issued by a company called Tether Limited that is governed by the laws of the British Virgin Islands, according to the legal part of its website. It is incorporated in Hong Kong. It has emerged that Jan Ludovicus van der Velde is the CEO of cryptocurrency exchange Bitfinex, which has been accused of being involved in the price manipulation of bitcoin, as well as tether. Many people trading on exchanges, including Bitfinex, will use tether to buy other cryptocurrencies like bitcoin. Tether Limited argues that using this method to buy virtual currencies allows users to move fiat in and out of an exchange more quickly and cheaply. Also, exchanges typically have rocky relationships with banks, and using Tether is a way to circumvent that.  USDT is fairly simple to use. Once on exchanges like Poloniex or Bittrex, it can be used to purchase Bitcoin and other cryptocurrencies. It can be easily transferred from an exchange to any Omni Layer enabled wallet. Tether has no transaction fees, although external wallets and exchanges may charge one. In order to convert USDT to USD and vise versa through the Tether.to Platform, users must pay a small fee. Buying and selling Tether for Bitcoin can be done through a variety of exchanges like the ones mentioned previously or through the Tether.to platform, which also allows the conversion between USD to and from your bank account.

Tether

Tether is trending due to its deepening strategic ties and significant ownership in Rumble, fostering community discussions around its influence on the platform's growth and enabling crypto payments for creators, while ongoing debates persist regarding its market cap and stability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study

RHHBY reports that giredestrant plus palbociclib misses the main PFS goal in a phase III first-line breast cancer study, though the combo shows a numerical improvement.

Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal

RHHBY says the ZUPREME-1 study meets its goal as petrelintide delivers up to 10.7% weight loss with placebo-like tolerability, supporting further advancement.

Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue?

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept's Korlym Drives its 2025 Revenue Surge: What's Ahead?

CORT's Korlym 2025 sales rises 13% Y/Y, with 2026 revenues seen at $900M-$1B. However, the court ruling favoring Teva's generic may put pressure on future sales.

Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead?

MRK's Keytruda posted $31.7B in 2025 sales. Can new approvals, ongoing studies and a revamped structure keep oncology growth strong through 2026?

Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study

RHHBY's fenebrutinib slashes RMS relapses by 51% in phase III, advancing its bid for a first high-efficacy oral therapy in MS.

Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates

SRPT posts a wider Q4 loss as Elevidys sales tumble, but revenues top estimates and 2026 guidance outlines a cautious recovery path.

The Zacks Analyst Blog Highlights Costco Wholesale, Roche, Lam Research, Spruce Power and IDT

Costco, Roche and Lam Research lead Zacks??? top stock reports, with standout gains and resilient fundamentals across sectors.

Top Stock Reports for Costco, Roche & Lam Research

Costco's resilient membership model, strong cash flow and e-commerce momentum position it to weather market turmoil and keep earnings growing.

FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug

FDA's acceptance of RHHBY's NDA for giredestrant plus everolimus in ER-positive breast cancer sets up a potential first oral SERD combo.

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Current Price	$54.65
Prev Close	$55.39
Open	$52.32
Dividend Yield	1.94%
50-Day Moving Average	$55.79
Beta	0.32
Avg. Volume	2.74M
PE Ratio	22.85

52-Week High	$60.85
52-Week Low	$34.75
Market Capitalization	$305.28B
EPS (Annual)	$2.44
Price to Book	8.26
Revenue Per Employee	$656,820.44

RHHBY
Roche Holdings AG ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RHHBY News

RHHBYRoche Holdings AG ADR